Expand volunteer programme to bolster NHS workforce, charity says
The move could help with staffing problems in the health service as well as slashing the cost of relying on agencies that supply temporary staff, experts said.
The Volunteer to Career programme has been piloted by the charity Helpforce in 48 NHS organisations across England.
It provides training, mentorship and support to help volunteers transition to professional roles.
Helpforce is now urging the Government to consider the scheme as part of its upcoming 10 Year Health Plan, claiming it could help fill around 23,600 frontline vacancies and related study placements by the end of the current Parliament in 2029.
According to the charity, around 107,000 NHS secondary care roles in England are vacant and the annual cost of using agency and bank staff has topped £10 billion.
Amerjit Chohan, chief executive of Helpforce, said: 'The success of the Volunteer to Career programme to date has been significant.
'Together with our partners in NHS trusts and other organisations, we've helped people who are interested in healthcare careers but don't have a background in the field to gain valuable experience before applying for paid roles.
'Through expertly designed and structured pathways, volunteers can find their niche without the immediate pressure of employment, while being upskilled and given confidence to take into job interviews.
'Since we launched the pilot initiative in 2022, hundreds of people have taken part, with 55% of them successfully transitioning from volunteering roles to paid careers in healthcare or associated courses – such as in nursing and midwifery.
'Our analysis shows that with the right investment, there's clear potential to supersize the opportunity, with conservative capacity for each of the 215 NHS trusts in England to support an average of 50 volunteers annually.
'We urge the Government to consider Volunteer to Career expansion within its upcoming NHS 10-Year Health Plan, unleashing the potential of home-grown healthcare talent.'
It comes after Prime Minister Sir Keir Starmer set out a number of measures to help bring down immigration on Monday.
The White Paper includes plans to end care worker visas for overseas recruitment.
Think tanks the King's Fund and the Health Foundation have backed Helpforce's call to the Government.
Dr Jennifer Dixon, Health Foundation chief executive, said the results of the pilot have been 'significant' and scaling it up ' has to be worthy of serious consideration by a government that's eager to get people back to work'.
Sarah Woolnough, chief executive of the King's Fund, added: 'At a time when the NHS is severely stretched and tackling long-standing and chronic workforce shortages, Helpforce is doing excellent, innovative work to support volunteers to explore opportunities for an NHS career.
'To implement Volunteer to Career on a mass scale would require strategic investment in volunteer managers across NHS Trusts, but such investment would likely be cost-effective when set against paying high fees to agencies that supply temporary staff and helping to reduce the health services' reliance on recruiting large numbers of healthcare staff from overseas.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
24 minutes ago
- The Independent
‘Ozempic for dogs' may be the next big thing in pet health
With the runaway success of drugs like Ozempic and Mounjaro effectively helping humans slim down, researchers and biotech firms are now sniffing out a new frontier: weight-loss drugs for dogs. With up to 60 per cent of dogs in the UK estimated to be overweight or obese, the market for such drugs could be considerable. Okava, a San Francisco-based bio-pharma company which specialises in pet health, is planning to run trials for a drug designed to mimic the effects of Ozempic, with the goal to produce an implant-version for dogs, which lasts six-months at a time. According to estimates on the company's website, the current market for such a product could be worth $10bn, and they hope to have a canine weight-loss drug available as early as 2028 or 2029. In human weight-loss drugs, the active ingredient in Mounjaro is called tirzepatide, and in Ozempic, it is semaglutide. Both work in similar ways, mimicking a natural hormone called GLP-1. This hormone regulates blood sugar and appetite, ultimately leading people to feel fuller longer and reducing food intake. The challenge for biotech firms is to reproduce that effect in dogs – a species well-known for practically limitless gorging. The hope is that an Ozempic-style drug may reduce dogs' begging behaviour, which many owners find it difficult to resist rewarding. Often, lack of appetite in dogs is associated with illness, meaning developing an effective drug that doesn't appear to make pets seem unwell is a fine balance. One such drug, named Slentrol, was launched in 2007, but did not sell well, partly due to how owners' perceived their pets behaviour when on the medication. Okava's planned implant, called OKV-119, contains a GLP-1 mimic called exenatide. Michael Klotsman, Okava's chief executive, said he hoped dogs' behavioural changes from OKV-119 would be quite different from illness-related appetite loss. 'What owners should expect to see is their pet eating appropriate portions without the previous food obsession – they'll still eat regularly and show interest in meals, just without the excessive begging, scavenging or gulping behaviour,' he told The Guardian. But not all tails are wagging. Vets have suggested that in most cases, dog owners would be better off avoiding obesity in their dogs through more exercise and by restricting their pets' diets. Caroline Allen, Chief Veterinary Officer at the RSPCA told The Independent: 'A healthy diet and exercise is the best way to keep our pets happy and well but we understand that owners can sometimes struggle to manage their pets' weight. There is currently little information about proposed weight-loss implants or vaccinations for animals, and owners shouldn't rely on them becoming available. 'Before resorting to these sorts of interventions, owners should seek help from their vet about how to reduce their pet's weight with a good diet and providing lots of opportunities to exercise and play in ways that their pet will enjoy." She added: 'It may be that weight loss jabs or implants may have a role to play in future in very limited circumstances where animals are clinically unwell, but the best thing we can do is set healthy habits from the start so our pets can live the best life possible.'
The Independent
an hour ago
- The Independent
Children's supplement recalled over fears it contains prescription-only sleep drug
A health alert has been issued to parents over a brand of children 's magnesium gummies after batches were found to contain a prescription-only drug used to aid sleep. Melatonin, which may cause drowsiness, headaches, dizziness and nausea, was detected in Kids Magnesium Glycinate Gummies made by Nutrition Ignition. The synthetic hormone is not listed on the packaging of the raspberry-flavoured gummies. Health chiefs have ordered the gummies to be removed from sale, working with online retailers to withdraw all listings. The Medicines and Healthcare products Regulatory Agency (MHRA) has warned parents to stop giving them to children and to safely dispose of any left. According to top US research school John Hopkins Medicine, people should not use melatonin if they have and autoimmune disorder, a seizure disorder or depression. It also says melatonin supplements may raise blood sugar. Experts at the agency, who tested two batches of the supplements, found between 1.5 and 1.7mg of melatonin in each gummy. The usual adult dose of prescription melatonin, to help severe sleep problems or to recover from jet lag, is 2mg. If prescribed for children, the recommended starting dose is 1mg but may be increased to up to 5mg a day. The product packaging advised one or two gummies per day, depending on the child's age. MHRA chiefs say advice should be sought from a healthcare professional if a child has any worrying side effects. According to the NHS, melatonin takes up to two hours to work. It is usually recommended for up to 13 weeks, and anyone taking it for a long time might need help to come off it. But the MHRA says lasting harm is not expected when ingesting melatonin at high levels, and the body typically clears it within 12 hours. Anyone who has the gummies at home is advised to store them in a tamper-proof container until they take it to a pharmacy for disposal. The gummies must now be regulated as a medicine. Nutrition Ignition Kids Magnesium Glycinate Gummies were promoted as supporting 'calm, focus and digestion '. Alison Cave, chief safety officer at the MHRA, said: 'Side-effects such as headache, hyperactivity, a feeling of dizziness and abdominal pain have been reported in children when melatonin is prescribed and used for its licensed indications. No serious side- effects were observed in studies in children. 'Anyone who suspects that their child or a child in their care is having a side-effect from this product is advised to stop taking it and speak to a healthcare professional and report it directly to the MHRA Yellow Card scheme.'
The Independent
an hour ago
- The Independent
Parents urged to stop using brand of children's magnesium gummies due to harmful side effects
Parents have been urged to stop giving their children a brand of gummies after testing revealed the presence of an undeclared prescription-only medicine for sleep disorders. Nutrition Ignition Kids Magnesium Glycinate Gummies claims to help reduce tiredness and boost the immune system, but now the Medicines and Healthcare products Regulatory Agency (MHRA) is working with online retailers to remove the product from sale. Magnesium glycinate is a dietary supplement that can help with anxiety and improve sleep. However, tests on two batches of this specific brand showed between 1.5 and 1.7mg of melatonin in each individual gummy. Melatonin, the hormone that helps regulate the sleep-wake cycle, is naturally produced by the body. However, a synthetic version is authorised for use on prescription in the UK for adults and children over the age of six with sleep disorders such as insomnia. If prescribed, the recommended starting dose is 1mg for children. According to the MHRA, melatonin is not listed anywhere on the packaging of Nutrition Ignition Kids Magnesium Glycinate Gummies. The packaging advises a dose of one to two gummies per day. Taking too much melatonin can cause headaches, drowsiness, dizziness and nausea. Dr Alison Cave, chief safety officer at MHRA, said: 'We advise any parent or caregiver to stop use of this product and safely dispose of it. ' Side effects such as headache, hyperactivity, a feeling of dizziness and abdominal pain have been reported in children when melatonin is prescribed and used for its licensed indications. No serious side effects were observed in studies in children. 'Anyone who suspects that their child, or a child in their care, is having a side effect from this product is advised to stop taking it and speak to a healthcare professional and report it directly to the MHRA Yellow Card scheme.' Nutrition Ignition Kids Magnesium Glycinate Gummies are sold online as a food supplement, but the MHRA has now removed the product from sale and is working with online retailers to remove all listings.
